2012 | |
---|---|
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
Networking Rank (Reputation): | > 1000 |
Total number of projects: 2
As coordinator: 0
As participant: 2
Sole participant: 0
Coordinator / Participant Ratio: 0*
Total project funding [€]: | Projects [No]: | |||||
---|---|---|---|---|---|---|
Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
2013 | 0 | 3.872.919 | 754.961 | 1 | ||
2012 | 0 | 5.976.298 | 398.420 | 1 |
Total number of partners: 20
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 20
Frequent / Rare Partner Ratio: 0
Start date | Project | acronym | role | funding | partners |
---|---|---|---|---|---|
2013-09-01 | Development of a universal influenza vaccine based on tandem core technology | FLUTCORE | participant | 3.872.919 | 7 |
2012-11-01 | "Transposon-based, targeted ex vivo gene therapy to treat age-related macular degeneration (AMD)" | TARGETAMD | participant | 5.976.298 | 15 |